Treatment of advanced atherosclerotic mice with the senolytic agent ABT-263 is associated with reduced indices of plaque stability and increased mortality https://www.biorxiv.org/content/10.1101/2023.07.12.548696v1?med=mas
Treatment of advanced atherosclerotic mice with the senolytic agent ABT-263 is associated with reduced indices of plaque stability and increased mortality https://www.biorxiv.org/content/10.1101/2023.07.12.548696v1?med=mas